These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2416212)

  • 1. Procainamide administration during continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ; Pitterle ME
    Am Heart J; 1985 Dec; 110(6):1306-8. PubMed ID: 2416212
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of procainamide and N-acetylprocainamide in patients undergoing continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ; Pitterle ME
    Clin Pharm; 1985; 4(6):669-72. PubMed ID: 2416503
    [No Abstract]   [Full Text] [Related]  

  • 4. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ
    Nephron; 1986; 44(3):191-4. PubMed ID: 2431330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical pharmacology of procainamide and its active metabolite -N-acetylprocainamide].
    Matusewicz W; Orszulak DE
    Przegl Lek; 1984; 41(5):379-83. PubMed ID: 6206523
    [No Abstract]   [Full Text] [Related]  

  • 6. Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity.
    Low CL; Phelps KR; Bailie GR
    Nephrol Dial Transplant; 1996 May; 11(5):881-4. PubMed ID: 8671917
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aging and renal clearance of procainamide and acetylprocainamide.
    Reidenberg MM; Camacho M; Kluger J; Drayer DE
    Clin Pharmacol Ther; 1980 Dec; 28(6):732-5. PubMed ID: 6160015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cimetidine inhibits renal procainamide clearance.
    Christian CD; Meredith CG; Speeg KV
    Clin Pharmacol Ther; 1984 Aug; 36(2):221-7. PubMed ID: 6204803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of desethyl procainamide in patients: a new metabolite of procainamide.
    Ruo TI; Morita Y; Atkinson AJ; Henthorn T; Thenot JP
    J Pharmacol Exp Ther; 1981 Feb; 216(2):357-62. PubMed ID: 6162026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition study of procainamide and N-acetylprocainamide during subacute administration in rats.
    Kamath BL; Lai CM; Krasula RW; Stampfli HF; Gupta SD; Yacobi A
    Toxicol Appl Pharmacol; 1982 Jan; 62(1):158-66. PubMed ID: 6175050
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lethal accumulation of procainamide metabolite in severe renal insufficiency.
    Vlasses PH; Ferguson RK; Rocci ML; Raja RM; Porter RS; Greenspan AM
    Am J Nephrol; 1986; 6(2):112-6. PubMed ID: 2422935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacokinetics and pharmacodynamics of novocainamide and its metabolite N-acetylnovocainamide].
    Kholodov LE; Glezer MG; Sokolov AV
    Kardiologiia; 1981 Nov; 21(11):119-26. PubMed ID: 6171667
    [No Abstract]   [Full Text] [Related]  

  • 19. Kinetics of N-acetylprocainamide deacetylation.
    Stec GP; Ruo TI; Thenot JP; Atkinson AJ; Morita Y; Lertora JJ
    Clin Pharmacol Ther; 1980 Nov; 28(5):659-66. PubMed ID: 6160014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of procainamide hydrochloride in dogs.
    Papich MG; Davis LE; Davis CA; McKiernan BC; Brown SA
    Am J Vet Res; 1986 Nov; 47(11):2351-8. PubMed ID: 2431636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.